Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425574 · ClinicalTrials.gov registry record
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
A clinical trial of Stargardt Disease and Stargardt Macular Dystrophy, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT07425574 is a study of Stargardt Disease and Stargardt Macular Dystrophy that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 90 participants, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07425574, a study of Stargardt Disease and Stargardt Macular Dystrophy, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to vision loss in the center of the eye. Side vision (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically happens in childhood, but many people do not develop it until they are adults. As well as STGD, there are other macular dystrophies that look very similar to STGD but that are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies. This is because they look the same clinically and have similar symptoms. Since different genes can cause these conditions, genetic testing is the only way to be sure which specific condition a person has. In this study, researchers want to learn if the disease progresses in a similar way in people with STGD and STGD-like macular dystrophies. People taking part in the study will continue to manage their condition, as agreed with their own doctor. People will visit their clinic every 6 months to have various standard eye tests and imaging. The information collected will include questions about people's wellbeing, general health, medication and supplements taken, and daily activities. Children over 6 years old and adults with STGD-type macular dystrophies may take part in this study. They will be in the study for up to 24 months (2 years). The study sponsor (Astellas) will not decide how people's condition is managed. However, the sponsor will provide instructions on when people visit their clinic and what is recorded during the study. If available, medical records, clinical and imaging data from previous visits going back 24 months will also be reviewed.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2028-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07425574
The ClinicalTrials.gov registry entry for NCT07425574 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT07425574 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07425574 about?
NCT07425574 is a clinical study titled "A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults". Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads...
What is the current status of trial NCT07425574?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2026-02-20. Estimated completion is 2028-07-31.
What conditions does trial NCT07425574 study?
This clinical trial studies the following conditions: Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy.
What interventions are being tested in trial NCT07425574?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT07425574?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07425574 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.